Based on the pharmacology of IGF-1 class compounds, risks include hypoglycemia, edema from fluid retention, potential promotion of existing neoplastic cells, and acromegalic features with long-term high-dose use
Positive results in these assays indicate the molecule has the structural characteristics needed for receptor engagement
However, a less-discussed concern is the loss of muscle, which is equally as concerning, so lets dive into that here
Understanding the distinct evidence base, regulatory status, and safety profile of each agent and the complete absence of clinical data on their combined use is essential for patients and healthcare professionals navigating this rapidly evolving and largely unregulated landscape
Scale bars: 10 m ( E and F insets), 50 m ( C , D , G and H )